9 results
8-K
EX-99.1
GLTO
Galecto Inc
5 Jan 22
Regulation FD Disclosure
4:02pm
in patients not on pirfenidone or nintedanib Key secondary outcomes: Safety, Diffusing Capacity for Carbon Monoxide (DLCO), 6-minute walk test, Quality of Life
10-K
2020 FY
GLTO
Galecto Inc
29 Mar 21
Annual report
6:03am
of GB1211 was evaluated in a mouse model of carbon-tetrachloride-induced liver fibrosis. In two separate studies, fibrosis was induced in mice, which were … with a standard measurement of collagen content using levels of hydroxyproline, a major component of collagen.
Figure 14. Oral GB1211 blocks carbon
8-K
EX-99.1
GLTO
Galecto Inc
5 Jan 21
Results of Operations and Financial Condition
4:31pm
of Life 14 * DLCO – Diffusing Capacity for Carbon Monoxide (*)
Ground-breaking novel treatment of IPF, an orphan disease with poorly tolerated
424B4
agvhcxl2anluulk
30 Oct 20
Prospectus supplement with pricing info
4:31pm
S-1/A
ahwub5v45jyr8 pn
22 Oct 20
IPO registration (amended)
6:13am
S-1
bnzwo2as
7 Oct 20
IPO registration
5:01pm
DRS
1m0 cdbum
2 Sep 20
Draft registration statement
12:00am
- Prev
- 1
- Next